Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The use of fondaparinux in preventing thromboembolism in high risk trauma patients

Next Previous
Trial Profile

The use of fondaparinux in preventing thromboembolism in high risk trauma patients

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fondaparinux sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use

Most Recent Events

  • 05 Oct 2008 Actual patient number (106) added as reported by ClinicalTrials.gov.
  • 05 Oct 2008 Status changed from recruiting to completed as reported by CT.gov
  • 05 Oct 2008 Actual end date (June 2008) added as reported by CT.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top